Narcolepsy Drugs Market size was valued at USD 3.63 Billion in 2023 and is projected to exceed USD 12.68 Billion by 2036, expanding at over 10.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of narcolepsy drugs is evaluated at USD 3.96 Billion. The rising prevalence of narcolepsy globally owing to the stressful lifestyle along with the surge in consumption of alcohol and tobacco is one of the major factors estimated to drive the growth of the narcolepsy drugs. As per the report, approximately 20% of American adults smoke, while 64% use alcoholic beverages regularly.
The market growth is also attributed to the increasing demand for the latest therapies to cure the disorder and rising healthcare expenditure in various emerging economies. Further, there is a significant rise in the activities of research & development for the development of highly effective drugs on the back of unhealthy lifestyles of people. Between 2000 and 2018, global health expenditure increased steadily, reaching US$ 8.3 trillion, or 10% of the global GDP.
The creation of drugs for narcolepsy treatment has accelerated dramatically in recent years. Furthermore, administrations in nations including India and South Africa are encouraging the manufacturing of narcolepsy drugs due to the health benefits, which are projected to enhance the narcolepsy drugs industry growth throughout the forecast period.
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
10.1% |
|
Base Year Market Size (2023) |
USD 3.63 Billion |
|
Forecast Year Market Size (2036) |
USD 12.68 Billion |
|
Regional Scope |
|
Disease Type (Extreme Sleepiness, Cataplexia)
Based on disease type, the market for narcolepsy drugs is segmented into extreme sleepiness, cataplexia, and others, out of which, extreme sleepiness is estimated to witness the highest market share owing to rising cases of narcolepsy worldwide along with the other disorders. During the projection period, the daytime extreme sleepiness segment is expected to hold the highest share of the market in the entire narcolepsy drugs market. The growth in narcolepsy prevalence increases the incidence of indications and other sleep disorders. Many patients with narcolepsy and other sleep disorders are more likely to experience this symptom, boosting the need for narcolepsy medicines. As additional firms enter the narcolepsy medicines industry, growth will be accelerated.
Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate)
The global market of narcolepsy drugs is also segmented and analyzed for demand and supply by application into Central Nervous System Stimulants, tricyclic antidepressants, selective serotonin reuptake inhibitors, sodium oxybate, and others. Amongst these three segments, the central nervous system stimulants segment is expected to garner a significant share of around 35% in the year 2036. During the projected period, the Central Nervous System Stimulants segment is anticipated to take over the market. Therapeutics including modafinil, armodafinil, and additional central nerve stimulants for narcolepsy are focused on enhancing wakefulness in individuals with narcolepsy, based to an article published in CNS Drugs named "Recently Approved and Upcoming Treatments for Narcolepsy" in January 2021.
End-user (Retail Pharmacies, Drug Stores, E-Commerce)
Increasing studies about central nervous system stimulants is likely to fuel segment growth. Harmony Biosciences Holdings, Inc., a drug manufacturer devoted to creating and advertising cutting-edge treatments for individuals with rare neurological conditions, released an assessment of data of CNS drugs in December 2021 that assessed the period before the onset of response to pitolisant for EDS and cataplexy in grown-up patients with narcolepsy. Such research is projected to lead to the creation of innovative central nervous system stimulants, propelling the expansion of this segment.
Our in-depth analysis of the global market includes the following segments:
|
By Disease Type |
|
|
By Therapeutics Type |
|
|
By End Users |
|
North American Market Forecast
The market in North America is anticipated to dominate the market owing to the rising prevalence of unhealthy lifestyles along with the technological advancements for the diagnosis of disease. Further, an increase in the number of narcolepsy cases leading to the rising awareness for the treatment along with rising healthcare expenditure is driving the growth of the market. Narcolepsy impacts between 135,000 and 200,000 individuals across the United States, in accordance to a data sheet published in November 2021 by the National Institute of Neurological Disorders and Stroke. However, owing to this condition is often incorrectly diagnosed, the number could be substantially higher. As a result of the elevated incidence of narcolepsy in advanced nations such as the United States, the growing use of narcolepsy treatment is expected to drive market expansion in this area.
APAC Market Statistics
The Asia Pacific region is estimated to witness the fastest growth rate on the back of economic development in major nations and rising investments in biotechnology sectors. In addition, the adoption of better standards of life and rising cases of sleep disorders is fostering the growth of the market. Japan has been identified as exhibiting a high frequency of narcolepsy among Asia Pacific countries. Governments in nations such as India are raising knowledge about the relevance of narcolepsy, which is projected to drive development in the narcolepsy drugs market over the forecast time frame. Moreover, the presence of established economic economies such as China and India is assisting in the development of healthcare facilities throughout the Asia-Pacific area. Furthermore, favorable government strategies in the Asia-Pacific region are encouraging the development of the narcolepsy drugs market. Other notable factors for expansion in this region's narcolepsy drugs market include multiple agreements between business entities and academic institutions in the region, along with an increase in the number of new products introduced, acquisitions, and product authorizations.
Europe Market Forecast
The Europe region is estimated to foresee lucrative growth on the account of rising research & development initiatives for the progress in narcolepsy novel drugs. In 2022, Europe held the second-largest market share. The key reasons for this are improved medical services and the region's growing population. This sector is also being boosted by government activities about depressive illness and its consequences. Other positive contributing elements include having finances accessible for research and operations, the expansion of the large patient population, and the increase in the number of obese people. Furthermore, the presence of established economic nations in European regions including Italy, Germany, and France. According to Eurostat, more than half of people in Europe are obese.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?